Table 1: Patient’s clinical and laboratory characteristics.

Clinical and laboratory characteristics Rapa group CsA group

Patients number 4345
Females/males29/1432/130.713
Mean age, years 34 (13–65)36 (14–58)0.456
Mean duration, years3 (2–6)3 (2–6)0.420
Mean bleeding grade (WHO Bleeding Scale)1 (0–2)1 (0–2)0.377
Mean baseline platelet count, ×109/L22.25 (11–32)21.82 (11–35)0.747
Mean MEG count in bone marrow slide105 (34–231)100 (34–241)0.710
Platetle antibody, yes/no28/1528/170.781
Mean days since the last treatment63 (10–365)57 (10–365)0.664
Mean numbers of previous treatments3 (2–6)3 (2–5)0.106
Previous treatments number4345
Steroids4345
Intravenous immune globulin1721
Danazol1619
Azathioprine1014
Vincristine21
Rituximab10

The previous treatments included Steroids, intravenous immune globulin, Rituximab, Danazol, Azathioprine, and Vincristine; the determination of platelet antibody included glycoproteins IIb/IIIa/Ib/IX.
MEG: megakaryocyte; Rapa: rapamycin; CsA: cyclosporine A.